GLP-1 Receptor Agonist and Your Cardiometabolic Health

Learn how GLP-1 receptor agonists can positively impact cardiometabolic health for better daily living and wellness.

Abstract

In this educational post, I will guide you through the evolving landscape of treating complex cardiometabolic conditions, focusing on Type 1 and Type 2 diabetes with associated cardiovascular and renal complications. From my perspective as Dr. Alex Jimenez, we will explore the latest evidence-based research, analyze detailed patient cases to understand clinical reasoning, and examine how our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, bridges care for heart failure and type 2 diabetes. I will outline the pathophysiology linking insulin resistance, chronic inflammation, and cardiometabolic remodeling, and explain why modern therapies like SGLT2 inhibitors and GLP-1 receptor agonists have transformed outcomes. This post details how our clinic integrates integrative chiropractic care, functional medicine, and medical oversight to provide comprehensive, patient-centered care that aims to prevent disease progression and improve quality of life.

A Collaborative Approach to Patient Care: The MD-Chiropractic Partnership

I am Dr. Alexander Jimenez, and my practice is built on a diverse background spanning chiropractic (DC), advanced practice nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP, ATN, CCST). At the Injury Medical Clinic PA, we believe that complex chronic diseases require a team-based strategy that addresses the body as an interconnected system.

This philosophy is embodied in our collaboration with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a board-certified internist with more than 40 years of invaluable experience. As our Medical Director and Collaborative Physician, she provides essential medical oversight, ensuring our treatment plans are both safe and grounded in the highest standards of conventional medicine. This multidisciplinary partnership, common in modern integrative and injury care clinics, allows us to blend the structural and neurological focus of chiropractic care—which is fundamental for musculoskeletal health and nervous system function—with the diagnostic and pharmacological expertise of internal medicine. The MD provides medical direction, medication management, and diagnostic oversight; the chiropractor leads neuromusculoskeletal assessment, conservative care, and functional rehabilitation; and our combined team synchronizes lifestyle, metabolic, and cardiometabolic risk modification.

Based on my clinical observations in practice and in the field (see healthcoach.clinic and my professional insights at linkedin.com/in/dralexjimenez), I’ve seen that patients with heart failure and type 2 diabetes improve most when we marry evidence-based cardiometabolic therapies with meticulous attention to biomechanics, sleep, autonomic balance, and inflammation.

Understanding the Cardiometabolic Bridge: Why Diabetes and Heart Failure Travel Together

When I explain to patients why diabetes and heart failure are “joined at the hip,” I start with insulin resistance. In type 2 diabetes, rising adiposity drives insulin resistance, leading to hyperglycemia and hyperinsulinemia. This hormonal and metabolic terrain fuels a cascade of damaging processes:

• Chronic low-grade inflammation: Adipose tissue releases pro-inflammatory cytokines such as TNF-? and IL-6.
• Endothelial dysfunction: The lining of blood vessels becomes impaired, reducing nitric oxide availability and hindering vasodilation.
• Dyslipidemia: An atherogenic lipid profile emerges, characterized by small, dense LDL particles and low HDL cholesterol.
• Neurohormonal activation: The renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system go into overdrive, increasing blood pressure and cardiac stress.
• Adverse myocardial remodeling: The heart muscle is bathed in pro-inflammatory cytokines from expanding epicardial adipose tissue (fat around the heart), leading to fibrosis, left ventricular hypertrophy (LVH), and autonomic dysfunction.

Physiologically, the heart remodels in response to this inflammatory and neurohormonal stress. The ventricle may become stiffer (diastolic impairment) or dilate and weaken (systolic impairment). Simultaneously, the kidney experiences glomerular hyperfiltration and fibrosis, accelerating chronic kidney disease (CKD). The net effect is the cardiorenal-metabolic syndrome.

HFpEF and HFrEF: Two Expressions of One Inflammatory Storm

Heart failure manifests in two primary ways, and distinguishing them is critical for therapy.

• Heart failure with preserved ejection fraction (HFpEF; EF> 50%): This is predominantly a diastolic dysfunction. The heart muscle becomes stiff and thickened, and is unable to relax properly (concentric LVH). It is tightly linked to obesity, type 2 diabetes, hypertension, and CKD. The core issues are systemic inflammation and microvascular endothelial dysfunction.
• Heart failure with reduced ejection fraction (HFrEF; EF <40%): This is primarily a systolic dysfunction or “pump failure” problem. The heart chamber dilates and weakens (eccentric remodeling), often after ischemic injury. Overactivation of RAAS and the sympathetic nervous system drives progressive pump failure.

Why this matters: HFrEF benefits from the “four pillars” of guideline-directed medical therapy (GDMT) that target these harmful neurohormonal pathways. HFpEF, historically harder to treat, responds best to therapies that reduce congestion, control metabolic risk factors, and target inflammation and fibrosis.

Game Changers in Treatment: SGLT2 Inhibitors and GLP-1 Receptor Agonists

The shift in diabetes care is no longer just about controlling glucose; it is about reducing cardiovascular events, kidney decline, and the burden of heart failure. Two medication classes—SGLT2 inhibitors and GLP-1 receptor agonists—stand out for achieving these goals.

Why SGLT2 Inhibitors Are a Pillar of Cardiometabolic Care

Mechanism in brief: By inhibiting the sodium-glucose co-transporter 2 in the kidney’s proximal convoluted tubule, SGLT2 inhibitors promote the excretion of glucose (glucosuria) and sodium (natriuresis).

Their cardiometabolic benefits are profound and multifaceted:

• Cardio-renal hemodynamics: They act as a gentle diuretic, reducing preload and afterload on the heart, which eases congestion. In the kidneys, they lower intraglomerular pressure, which protects against hyperfiltration injury.
• Myocardial energetics: They induce a state of low-level ketogenesis. The failing heart can use these ketone bodies as a “superfuel,” which it oxidizes more efficiently than glucose, improving cardiac work efficiency.
• Anti-inflammatory and antifibrotic signals: They reduce oxidative stress and profibrotic pathways, which correlates with improved ventricular compliance and better renal outcomes.
• Metabolic benefits: They lead to modest weight loss and reductions in blood pressure, further easing the heart’s workload.

The evidence is undeniable. Trials like EMPEROR-Reduced and DAPA-HF cemented SGLT2 inhibitors as a core therapy for HFrEF. EMPEROR-Preserved was the first major positive trial in HFpEF, showing a reduction in hospitalizations. Meanwhile, EMPA-KIDNEY, CREDENCE, and SCORED demonstrated powerful kidney protection.

Where GLP-1 Receptor Agonists Fit

Mechanism in brief: GLP-1 receptor agonists mimic a naturally occurring gut hormone to improve glucose-dependent insulin secretion, suppress glucagon secretion, slow gastric emptying, and promote satiety in the brain.

Their cardiometabolic benefits are centered on weight and atherosclerosis:

• Atherosclerotic CV disease (ASCVD) risk reduction: Landmark trials such as LEADER (liraglutide) and SUSTAIN-6 (semaglutide) demonstrated significant reductions in major adverse cardiovascular events (MACE). The SELECT trial critically demonstrated this benefit in people with obesity without diabetes, highlighting mechanisms beyond glucose control.
• Weight and metabolic inflammation: Meaningful weight loss (15-16% in STEP trials) reduces epicardial fat and systemic cytokine load, relieving hemodynamic and metabolic stress on the heart.
• Renal and vascular protection: They reduce albuminuria and improve endothelial function, contributing to plaque stability.

In our clinic, Dr. Cardenas and I use SGLT2 inhibitors for nearly all eligible patients with heart failure. We layer on a GLP-1 RA for those with coexisting obesity or ASCVD to target weight, inflammation, and plaque biology.

The Unmet Needs of Type 1 Diabetes: A Case Study of James

While SGLT2s and GLP-1s have revolutionized Type 2 diabetes care, my heart goes out to my patients with Type 1 diabetes, as these drugs are not officially approved for them. This is a significant gap, as they can develop aggressive kidney and heart disease. Let’s examine the case of James, a 57-year-old man.

Patient Profile: James

• Diagnosis: Latent Autoimmune Diabetes in Adults (LADA), a form of Type 1 diabetes, for 22 years.
• Glycemic Control: A1C of 7.9% on an insulin pump.
• Physical Exam: BMI of 38 (obese), blood pressure 136/88 mmHg.
• Comorbidities: Stage 3A CKD, established CAD with stents, and heart failure with moderately reduced ejection fraction (HFmrEF) with an EF of 48%. His lipids are poorly controlled on a low-intensity statin.

Crafting a Modern Treatment Plan for James

James’s case demands an aggressive, multi-pronged approach that goes beyond his current regimen.

1. Lipid and Blood Pressure Control: His pravastatin is insufficient. For a patient with his risk profile, a high-intensity statin like rosuvastatin is non-negotiable to drive his LDL down. His losartan dose also needs optimization.
2. Considering Off-Label Use of SGLT2 Inhibitors: This is a compelling option. The drug offers profound benefits for reducing heart failure hospitalizations and slowing nephropathy. The major risk is euglycemic Diabetic Ketoacidosis (DKA)—a dangerous condition where ketoacidosis occurs without high blood sugar. If we proceed, it must be “off-label” with extreme caution and patient education on monitoring for ketones.
3. The Role of a GLP-1 Receptor Agonist: This is also highly appropriate for promoting weight loss, reducing his MACE risk, and lowering his insulin needs. His triglyceride level does not put him at high risk for pancreatitis.
4. Navigating Insurance and Access: Getting these off-label drugs covered is a challenge. We can leverage other indications. For example, SGLT2 inhibitors are approved for heart failure regardless of diabetes status. Some GLP-1 agonists are approved for weight management, which could be a “backdoor” route to coverage for his obesity.

Managing the Complex Patient: The Case of Karen

Now let’s turn to Karen, a 70-year-old female with HFrEF, Type 2 diabetes, and Stage 4 CKD.

Patient Profile: Karen

• Comorbidities: HFrEF (EF 30%), Stage 4 CKD (eGFR 24), T2D, CAD, and COPD.
• Current Status: Low-normal blood pressure (90/70), no fluid overload.
• Labs: Borderline high potassium (5.2), high creatinine (2.3).
• Medications: She is on all four pillars of GDMT, including an ARNI (Entresto) and an MRA (eplerenone).

The Clinical Dilemma: To Add or Subtract?

Seeing Karen’s labs, many clinicians would instinctively start de-prescribing. I urge you to resist that instinct.

• Should We Add an SGLT2 Inhibitor? Absolutely, unequivocally, yes. Karen has two powerful indications: HFrEF and T2D. Since her eGFR is above 20, she is a clear candidate for its heart and kidney-protective benefits.
• What About the Expected GFR Drop? When an SGLT2 inhibitor is started, it causes a transient, expected drop in eGFR. This is not kidney injury; it is a sign the drug is working. We must ride out this initial dip to achieve long-term benefits.
• Should We Stop Any Medications? Yes, her diuretic. She is not congested, and her new SGLT2 inhibitor also has a diuretic effect. A practical rule is to reduce the loop diuretic dose by 50% when starting an SGLT2 inhibitor.
• What About the High Potassium and the MRA? I would not stop her MRA. A potassium of 5.2 is acceptable. Wonderfully, SGLT2 inhibitors can blunt the potassium-raising effect of MRAs, allowing us to keep patients on these life-saving drugs.

Our Integrated Clinical Protocol: Merging Medicine and Movement

With Dr. Cardenas providing medical oversight, our team executes a unified plan.

Baseline Phenotyping and Risk Staging

• Internal Medicine Assessment (Dr. Cardenas): A full workup including history, exam, ECG, echocardiogram, and labs (NT-proBNP, A1c, lipids, renal panel).
• Functional Medicine Mapping (My Role): We map dietary patterns, sleep quality, GI function, and inflammatory markers to identify root contributors such as visceral adiposity.
• Chiropractic and Biomechanical Screen: I assess posture, thoracic mobility, and breathing patterns. I pay close attention to thoracic stiffness and diaphragmatic inhibition, as these can elevate sympathetic tone and worsen dyspnea.

Initiating Evidence-Based Pharmacotherapy

• Cardenas supervises the initiation of SGLT2 inhibitors, GLP-1 RAs, and the four pillars of HFrEF therapy, carefully monitoring blood pressure, renal function, and electrolytes. We often deprescribe legacy medications like sulfonylureas to reduce hypoglycemia risk.

Integrated Chiropractic and Rehabilitation Approach

Patients often ask why chiropractic matters for heart failure. Here is how we embed it responsibly:

• Improving Respiratory Mechanics: Thoracic and rib dysfunction can amplify breathlessness. I use gentle mobilization or high-velocity, low-amplitude (HVLA) techniques to the thoracic spine and ribs, combined with diaphragmatic breathing. Optimizing rib cage compliance reduces the work of breathing and can decrease sympathetic outflow. My clinical observation aligns with patient-reported improvements in breathlessness after targeted manual therapy.
• Enhancing Autonomic Balance: Joint mechanoreceptor input from spinal adjustments can modulate central autonomic networks. When combined with HRV biofeedback and slow nasal breathing, we see improved heart rate variability, a marker of better cardiometabolic prognosis.
• Lowering Biomechanical Load: Corrective exercises for posture and gait improve kinetic chain efficiency, lowering the cardiometabolic cost of ambulation in deconditioned patients.

Functional Medicine and Lifestyle Therapeutics

• Nutrition: We employ a Mediterranean-style dietary template to ensure adequate protein and fiber intake while managing glycemic load.
• Physical Activity: We prescribe graduated aerobic conditioning and resistance training, which improves mitochondrial biogenesis and insulin sensitivity.
• Sleep Optimization: We aggressively address sleep apnea and circadian disruption, as both worsen hypertension and insulin resistance.

Safety Monitoring and Collaboration

Dr. Cardenas and I hold weekly team huddles to review complex cases and align medication titration with rehab progression. We meticulously monitor volume status, eGFR, potassium, and GI effects, especially during the first 90 days of therapy.

---

Optimizing Your Wellness- Video

---

Practice Pearls and a New Paradigm in Patient Education

1. Rethinking Fluid and Salt Restriction: Strict restrictions are becoming obsolete. Modern drugs like ARNIs and SGLT2 inhibitors are potent natriuretics. Forcing fluid restriction on top of these can lead to dehydration and malnutrition. The new advice: let patients listen to their bodies.
2. The Power of Class Effect: Think in terms of medication classes that treat multiple comorbidities simultaneously. An SGLT2 inhibitor is a heart failure drug, a kidney drug, and a diabetes drug.
3. The Importance of Early Intervention: Do not wait for a patient’s condition to worsen. The goal is to prevent the progression of disease. Preserving organ function is paramount.

What Success Looks Like

Under Dr. Cardenas’ medical direction and our integrated approach, we routinely see fewer HF exacerbations, improved 6-minute walk distances, sustained weight loss and A1c reductions, and better blood pressure control. This is the power of combining cardioprotective drugs with hands-on care, enabling patients to move, breathe, and sleep better. The science supports it; the lived outcomes inspire it.

References

• Anker, S. D., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461.
• Bhatt, D. L., et al. (2021). Sotagliflozin in patients with diabetes and chronic kidney disease: SCORED. New England Journal of Medicine, 384(2), 129–139.
• Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., McMurray, J. J. V., Prescott, M. F., & Zannad, F. (2021). Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 77(18), 2261–2272.
• McMurray, J. J. V., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). New England Journal of Medicine, 381(21), 1995–2008.
• Marso, S. P., et al. (2016a). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine, 375(4), 311–322.
• Marso, S. P., et al. (2016b). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine, 375(19), 1834–1844.
• Packer, M., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). New England Journal of Medicine, 383(15), 1413–1424.
• Perkovic, V., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE). New England Journal of Medicine, 380(24), 2295–2306.
• Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Tschirhart, H., Zinman, B., Mazze, R. S., Fagan, S., Krolewski, A. S., Lytvyn, Y., & von Eynatten, co-transporterdium–glucose co-transporter 2 inhibition and glycemic control in type 1 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetologia, 62(11), 1947–1956.
• SELECT Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine.
• The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388(2), 117–127.

SEO Tags: heart failure and diabetes, HFpEF, HFrEF, type 1 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, empagliflozin, dapagliflozin, semaglutide, integrative chiropractic, functional medicine, cardiometabolic syndrome, autonomic balance, diaphragm breathing, thoracic mobility, chronic kidney disease, euglycemic DKA, off-label prescribing, El Paso Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC